title: The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
authors.affiliation: Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. i.desar@aig.umcn.nl
authors.forename: Ingrid M E
authors.initials: IM
authors.lastname: Desar
authors.forename: Sasja F
authors.initials: SF
authors.lastname: Mulder
authors.forename: Alexander B
authors.initials: AB
authors.lastname: Stillebroer
authors.forename: Dick-Johan
authors.initials: DJ
authors.lastname: van Spronsen
authors.forename: Winette T A
authors.initials: WT
authors.lastname: van der Graaf
authors.forename: Peter F A
authors.initials: PF
authors.lastname: Mulders
authors.forename: Carla M L
authors.initials: CM
authors.lastname: van Herpen
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010997:Pleural Neoplasms / Q000188:drug therapy / Q000503:physiopathology* / Q000556:secondary; D011725:Pyridines / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077157:Sorafenib; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib